US Food and Drug Administration (USFDA) has successfully completed inspection at SMS Pharmaceuticals’ Active Pharmaceutical Ingredient (API) manufacturing facility situated at Visakhapatnam, Andhra Pradesh. The inspection, conducted from December 08, 2025 to December 12, 2025, concluded with one minor observation in Form 483. The observation is procedural in nature and does not relate to data integrity.
The company will provide the necessary response to USFDA within the stipulated time period. The Vizag facility is a 3,000 KL flagship, multipurpose API manufacturing facility, specialising in niche, large-volume molecules. It is backed by multiple global regulatory approvals, including USFDA, WHOGMP, EU-GMP, KFDA, CDSCO, and PMDA.
SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specialising in API and intermediates for global customers.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.70 |
| Dr. Reddys Lab | 1327.00 |
| Cipla | 1300.90 |
| Zydus Lifesciences | 930.65 |
| Lupin | 2285.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: